Janus Living, Inc. (JAN) Competitive Analysis & Comparison (2026)

Quality vs Value comparison of Janus Living, Inc. (JAN) and competitors
Company	Ticker	Quality Score	Value Score	Classification
Janus Living, Inc.	JAN	93%	60%	High Quality
Welltower Inc.	WELL	40%	70%	Value Play
Ventas, Inc.	VTR	93%	60%	High Quality
CareTrust REIT, Inc.	CTRE	53%	50%	High Quality
Omega Healthcare Investors, Inc.	OHI	13%	50%	Value Play
National Health Investors, Inc.	NHI	20%	20%	Underperform
Sabra Health Care REIT, Inc.	SBRA	13%	60%	Value Play

Janus Living, Inc. (JAN) enters the public markets as a highly unique entity within the healthcare REIT space. Spun out from Healthpeak Properties in March 2026, JAN operates exclusively as a pure-play senior housing REIT with a 100% RIDEA (REIT Investment Diversification and Empowerment Act) structure. This means unlike traditional REITs that simply collect fixed rent from tenants on a "triple-net" basis, JAN participates directly in the operational profits and losses of its 34 senior housing communities. By sidestepping fixed rent caps, JAN is perfectly positioned to capture maximum upside from the accelerating demand driven by the aging baby boomer generation. However, this operational exposure acts as a double-edged sword. While JAN can benefit from rising resident fees in a high-demand market, it also directly bears the brunt of operational risks such as wage inflation, staffing shortages, and localized occupancy dips. Most competitors buffer these risks by mixing their portfolios with stable, triple-net leases or medical office buildings. JAN's lack of diversification makes its cash flows inherently more volatile than its legacy peers, demanding a higher risk tolerance from retail investors. What truly sets Janus Living apart from the competition, however, is its pristine, debt-free capitalization. The company went public with zero debt and secured a massive credit facility, leaving it with nearly $1 billion in dry powder. In an industry currently bogged down by high interest rates and rolling maturity walls, JAN possesses the unencumbered flexibility to aggressively acquire distressed or under-managed properties at a time when capital is scarce. It is essentially a well-funded, blank-check operator in a sector desperate for liquidity, making it a high-risk, high-reward growth vehicle compared to the mature dividend-payers it competes against.

Welltower is the undisputed titan of the healthcare real estate sector, dwarfing Janus Living in both scale and operational maturity. While Welltower operates a highly diversified portfolio spanning senior housing, outpatient medical, and health systems across multiple countries, JAN is a highly concentrated, newly public spin-off entirely focused on U.S. senior housing. Welltower's primary strength lies in its unmatched data analytics, proprietary management systems, and premium valuation which gives it a deeply advantaged cost of capital. Conversely, JAN's strength rests entirely on its debt-free balance sheet and pure-play exposure to private-pay senior housing. The core risk for Welltower is the sheer size required to move its growth needle, whereas JAN faces extreme concentration risk and a complete lack of public-market track record.

When evaluating the Business & Moat, Welltower maintains a crushing advantage across the board. In terms of brand, Welltower's global footprint of 2,500+ properties vastly overshadows JAN's local footprint of 34 communities. Switching costs are relatively even, as both benefit from resident relocation friction averaging ~24 months per stay. In scale, Welltower commands over 150,000 beds versus JAN's 10,422 units. For network effects, Welltower leverages over 1 billion data points across its massive operator ecosystem, while JAN relies solely on its localized Healthpeak legacy network. Both face similar regulatory barriers, as local Certificate of Need (CON) laws restrict new national supply to roughly 2,500 new unit starts per quarter. For other moats, Welltower possesses an A- credit rating granting cheap debt access, whereas JAN is unrated. The overall winner for Business & Moat is Welltower, as its global scale and proprietary data systems create an insurmountable barrier to entry.

In Financial Statement Analysis, the comparison highlights a battle between mature cash flow and a pristine balance sheet. For revenue growth, JAN's +6.3% MRQ slightly edges out Welltower's +5.9% MRQ due to a smaller base. On margins, Welltower's 25.4% operating margin easily beats JAN's 21.2% operating margin driven by vast economies of scale. Looking at ROE/ROIC, Welltower is better with a 5.1% ROIC compared to JAN's negative 3.4% ROIC as JAN absorbs IPO costs. For liquidity, JAN is better on a relative basis with $1.0 billion available against a tiny asset base, though Welltower holds $10.2 billion available absolutely. On net debt/EBITDA, JAN is vastly superior at 0.0x compared to Welltower's 3.0x. For interest coverage, JAN is better with an infinite ratio (no debt) versus Welltower's 5.6x. On FCF/AFFO, Welltower is better generating $1.45 FFO/share while JAN currently posts a negative EPS base. For payout/coverage, JAN is better for retaining capital at a 0% payout versus Welltower's 81% payout. The overall Financials winner is Welltower, because its highly profitable, proven cash generation trumps JAN's non-earning cash pile.

Past Performance heavily favors the established incumbent. Comparing growth, Welltower's +12% / +8% / +6% 1/3/5y FFO CAGR for the 2021-2026 period defeats JAN's N/A / N/A / N/A since JAN has no operational history. On margin trends, Welltower expanded margins by +270 bps while JAN is N/A. For TSR incl. dividends, Welltower wins handily with a +55% TSR over 5 years compared to JAN's +2% TSR since its March IPO. On risk metrics, Welltower offers a known -35% max drawdown while JAN's beta remains N/A. The overall Past Performance winner is Welltower, simply by default of having a highly successful, multi-year track record while JAN has none.

For Future Growth, the drivers favor JAN's agility. TAM/demand signals are even as both target the 70 million aging baby boomers. In pipeline & pre-leasing, JAN has the edge, as its $1 billion pipeline allows for massive percentage growth relative to its size compared to Welltower's $3 billion recent run-rate. For yield on cost, Welltower has the edge at 8.0% yields versus JAN's estimated 7.5% yields. For pricing power, Welltower has the edge, pushing +9.6% rent hikes versus JAN's +8.5%. On cost programs, Welltower has the edge through its proprietary "Welltower Business System." On refinancing/maturity wall, JAN has a massive edge with a 0% maturity wall versus Welltower rolling over billions in debt. For ESG/regulatory tailwinds, both are even with strong green-building initiatives. The overall Growth outlook winner is JAN due to its unconstrained capital deployment runway, though the primary risk is that JAN's management lacks Welltower's historical integration expertise.

Fair Value analysis reveals differing premiums. For P/AFFO, JAN is cheaper at an estimated 20.0x versus Welltower's premium 34.0x as of June 2026. On EV/EBITDA, JAN is cheaper at ~22.0x versus Welltower's 25.0x. For P/E, both are largely unhelpful but JAN is negative while Welltower trades at high multiples. For implied cap rate, JAN is cheaper at ~5.5% compared to Welltower's ~4.5%. On NAV premium/discount, JAN is better value trading at a -5% discount compared to Welltower's +15% premium. For dividend yield, Welltower wins with a 1.4% yield while JAN yields 0.0%. Ultimately, Welltower commands a premium price for premium quality, but JAN offers a cheaper entry point to the same demographic tailwinds. The better value today is JAN, purely on a metric-basis, because it trades at a discount to its net asset value while WELL is priced for perfection.

Winner: Welltower over Janus Living. Welltower's global scale (2,500+ properties), established operator network, and massive proprietary data pool make it a far superior, battle-tested investment. While JAN possesses an incredibly attractive debt-free balance sheet (0.0x leverage) and $1 billion in dry powder, it carries the extreme risk of being an unproven, concentrated entity with negative trailing earnings. Welltower justifies its premium valuation by consistently generating double-digit FFO growth and providing a safe, reliable dividend that JAN currently lacks. Ultimately, Welltower's sheer operational dominance and A- credit rating provide a level of safety and execution certainty that a newly minted spin-off cannot match.

Ventas is a massive, highly diversified healthcare REIT that directly competes with Janus Living in the senior housing operating portfolio (SHOP) space. Ventas brings decades of experience, a diversified portfolio including life science and medical office buildings, and a robust data-analytics platform called Ventas OI. In contrast, JAN is a hyper-focused, pure-play senior housing REIT that lives and dies by the operational performance of its 34 properties. Ventas offers a secure dividend and vast institutional relationships, but it carries legacy debt and slower aggregate growth. JAN offers explosive growth potential via its debt-free balance sheet, but exposes investors to higher volatility and concentration risks.

In the Business & Moat comparison, Ventas holds the high ground. For brand, Ventas dominates with 900+ properties against JAN's 34 properties. Switching costs are even, as both maintain resident retention averaging ~20 months. For scale, Ventas serves over 96,000 residents compared to JAN's 10,422 units. In network effects, Ventas wins by leveraging 1 billion data points to optimize operations, while JAN has a minimal localized data pool. Regulatory barriers are even, as both face local zoning and development restrictions. For other moats, Ventas wins with a trusted operator network spanning 40+ partners, whereas JAN relies heavily on legacy Healthpeak relationships. The overall winner for Business & Moat is Ventas, driven by its massive operational footprint and proprietary data systems that optimize pricing and occupancy.

Financial Statement Analysis shows a mature operator versus a clean slate. For revenue growth, Ventas is better with +9.0% MRQ versus JAN's +6.3% MRQ. On margins, Ventas is better at 23.5% operating margin compared to JAN's 21.2% operating margin. Looking at ROE/ROIC, Ventas is better with a 6.0% ROIC versus JAN's negative 3.4% ROIC. For liquidity, Ventas is better in absolute terms with $3.0 billion available versus JAN's $1.0 billion available. On net debt/EBITDA, JAN is vastly superior at 0.0x compared to Ventas's 6.0x. For interest coverage, JAN is better with an infinite ratio against Ventas's 3.5x. On FCF/AFFO, Ventas is better, generating $0.94 FFO/share in Q1 2026 while JAN posted negative EPS. For payout/coverage, JAN is better for capital retention at a 0% payout versus Ventas's 55% payout. The overall Financials winner is Ventas, because its strong SHOP NOI margin expansion and steady FFO generation easily outweigh JAN's currently un-deployed cash pile.

Past Performance heavily favors Ventas. On growth, Ventas is better with +8% / +5% / +2% 1/3/5y FFO CAGR for 2021-2026 compared to JAN's N/A. For margin trend, Ventas expanded SHOP margins by +150 bps while JAN remains N/A. For TSR incl. dividends, Ventas wins with a +30% TSR over 5 years versus JAN's +2% TSR since IPO. On risk metrics, Ventas is a known quantity with a -45% max drawdown while JAN's beta is N/A. The overall Past Performance winner is Ventas, as it has a documented history of successfully navigating complex macro environments while JAN does not.

Future Growth drivers present a mixed picture. TAM/demand signals are even due to the identical macro tailwinds of the aging population. For pipeline & pre-leasing, JAN has the edge, as its $1 billion in liquidity can radically transform its small asset base, while Ventas's $3 billion 2026 pipeline moves the needle less. For yield on cost, Ventas has the edge at 8.0% yields versus JAN's 7.5% yields. For pricing power, JAN has the edge with a concentrated +8.5% rent bump in pure private-pay assets versus Ventas's blended +6.0%. On cost programs, Ventas has the edge through its Ventas OI technology platform. For refinancing/maturity wall, JAN has a massive edge with a 0% maturity wall versus Ventas's continuous debt rolls. For ESG/regulatory tailwinds, both are even. The overall Growth outlook winner is JAN, purely because its zero-debt capital structure allows for unconstrained, highly accretive external acquisitions. The risk to this view is that JAN overpays for assets in a competitive market.

Valuation metrics highlight a solid deal for Ventas. For P/AFFO, both are largely comparable with Ventas at 21.0x and JAN estimated at 20.0x as of June 2026. For EV/EBITDA, Ventas is better at 19.0x versus JAN's 22.0x as of June 2026. On P/E, Ventas is better at ~35.0x while JAN is negative. For implied cap rate, Ventas offers better value at ~6.0% versus JAN's ~5.5%. On NAV premium/discount, both trade at a rough ~5% discount to NAV. For dividend yield, Ventas is better with a 2.5% yield paying $0.52 per quarter versus JAN's 0.0% yield. Quality vs price suggests Ventas offers a stable yield at a fair price, while JAN is a non-yielding speculative play. The better value today is Ventas, as it provides immediate, predictable cash returns at a nearly identical multiple to JAN's speculative valuation.

Winner: Ventas over Janus Living. Ventas provides a vastly superior risk-adjusted return profile due to its immense scale (900+ properties), established $0.52 quarterly dividend, and sophisticated data-driven operational platform. While JAN offers an alluring pure-play upside and a flawless 0.0x debt profile, its lack of diversification and negative trailing earnings make it highly speculative. Ventas has proven its ability to consistently drive double-digit NOI growth in its senior housing operating portfolio while insulating itself with medical office buildings. Ultimately, retail investors are better served by the proven cash flow and stability of Ventas rather than the high-stakes, highly concentrated operational bet that JAN represents.

CareTrust REIT represents a fundamentally different approach to healthcare real estate than Janus Living. While JAN is a 100% RIDEA pure-play senior housing operator directly exposed to facility profits and losses, CareTrust operates primarily under triple-net leases, focusing on skilled nursing and senior housing. This means CTRE collects fixed rent checks while operators bear the brunt of inflation and staffing woes. CTRE is defined by its ultra-conservative balance sheet, aggressive recent acquisition spree, and incredibly stable margins. JAN, conversely, is defined by its lack of debt and high-leverage operational upside. If you want income safety, CTRE is the standard; if you want operational torque, JAN is the vehicle.

In Business & Moat, CareTrust's tenant lock-in stands out. For brand, CTRE is larger with 200+ properties compared to JAN's 34 properties. On switching costs, CTRE dominates with 10-to-15 year triple-net master leases versus JAN's annual resident leases. For scale, CTRE is better with a broader national footprint compared to JAN's 10,422 units concentrated heavily in FL/TX. On network effects, CTRE wins by managing dozens of operator relationships compared to JAN's narrow legacy network. For regulatory barriers, CTRE is better protected as its skilled nursing assets require strict Medicaid bed licenses limiting new competition, whereas JAN's private-pay market is easier to enter. For other moats, CTRE's triple-net structure perfectly insulates it from operating costs, unlike JAN's total exposure. The overall winner for Business & Moat is CareTrust, as its long-term triple-net master leases provide incredibly durable switching costs and margin safety.

Financials reveal CTRE's cash-generating prowess. For revenue growth, CTRE wins massively with +58.4% MRQ driven by heavy acquisitions, against JAN's +6.3% MRQ. On margins, CTRE's 40.2% operating margin destroys JAN's 21.2% operating margin due to its zero-overhead NNN lease structure. For ROE/ROIC, CTRE is better at 8.5% ROE compared to JAN's negative 4.9% ROE. On liquidity, JAN is better with $1.0 billion available versus CTRE's $400 million. For net debt/EBITDA, JAN's 0.0x technically beats CTRE's exceptionally low 0.6x. On interest coverage, JAN is better (infinite) versus CTRE's 8.5x. For FCF/AFFO, CTRE wins by generating $1.76 AFFO/share compared to JAN's negative EPS. For payout/coverage, JAN's 0% payout allows total reinvestment compared to CTRE's 70% payout. The overall Financials winner is CareTrust, as its extremely low-leverage profile coupled with massive revenue growth and high margins makes it an absolute cash-printing machine.

Past Performance metrics are entirely lopsided. For growth, CTRE wins with +15% / +12% / +10% 1/3/5y FFO CAGR for 2021-2026 versus JAN's N/A. On margin trends, CTRE expanded by +150 bps while JAN is N/A. For TSR incl. dividends, CTRE wins significantly with a +65% TSR over 5 years versus JAN's +2% TSR since IPO. On risk metrics, CTRE proved its resilience with a -25% max drawdown during bear markets, while JAN's beta is N/A. The overall Past Performance winner is CareTrust, which has consistently delivered market-beating shareholder returns and dividend hikes over a long, verifiable history.

Future Growth drivers highlight differing strategies. TAM/demand signals are even across the aging demographic spectrum. For pipeline & pre-leasing, JAN has the edge with a $1 billion unencumbered pipeline compared to CTRE's steady but smaller relative deal flow. On yield on cost, CTRE has the edge, securing 9.0% yields on recent skilled nursing deals versus JAN's 7.5% yields on senior housing. For pricing power, JAN has the edge capturing +8.5% rent bumps in an inflationary environment, whereas CTRE is locked into +2.5% fixed escalators. On cost programs, CTRE has the edge as the tenant bears costs. For refinancing/maturity wall, JAN is better with a 0% near-term maturity wall. On ESG/regulatory tailwinds, JAN has the edge as it completely sidesteps CTRE's Medicare/Medicaid reimbursement risks. The overall Growth outlook winner is JAN, as its unhedged structure allows it to capture 100% of the upside in a booming senior housing market. The primary risk to this view is that zero fixed leases means zero downside protection if occupancy falls.

Valuations favor the proven operator. For P/AFFO, CTRE is better value at 19.0x versus JAN's estimated 20.0x as of June 2026. On EV/EBITDA, CTRE is better at 18.5x versus JAN's 22.0x as of June 2026. For P/E, CTRE is better at 25.0x while JAN is negative. On implied cap rate, CTRE is better at 6.5% versus JAN's 5.5% as of June 2026. For NAV premium/discount, JAN is cheaper at a -5% discount versus CTRE's +10% premium. On dividend yield, CTRE is vastly superior, offering a 4.0% yield versus JAN's 0.0% yield. Quality vs price shows CTRE commands a justified premium for execution, while JAN is a cheaper asset-play. The better value today is CareTrust, as investors can acquire a highly profitable, 4%-yielding machine at a lower multiple than JAN's unproven operations.

Winner: CareTrust over Janus Living. CareTrust offers a nearly flawless combination of low leverage (0.6x Net Debt/EBITDA), high operating margins (40.2%), and a robust 4.0% dividend yield. While JAN has the theoretical advantage of zero debt and uncapped private-pay upside, it currently operates at a loss and forces investors to take on full operational risk. CareTrust's triple-net lease structure mathematically insulates it from the vicious wage inflation and staffing shortages that plague direct operators like JAN. For a retail investor, CareTrust provides significantly more safety, a proven track record of double-digit FFO growth, and immediate cash returns, making it the unambiguously superior investment.

Omega Healthcare Investors is a high-yield, legacy REIT primarily focused on skilled nursing facilities (SNFs) via triple-net leases. Omega acts as a capital provider to operators who rely heavily on government Medicare/Medicaid reimbursements. Janus Living sits on the exact opposite side of the spectrum: it is a pure-play, private-pay senior housing operator under a RIDEA structure with no government reimbursement risk. OHI provides massive current income and deals with frequent tenant credit headaches, while JAN provides zero current income but enjoys the safety of wealthy, out-of-pocket paying seniors.

In Business & Moat, Omega wins on pure scale and lock-in. For brand, OHI's massive 1,124 properties easily beats JAN's 34 properties. On switching costs, OHI is superior with 10-to-12 year master leases versus JAN's monthly or annual resident agreements. For scale, OHI controls 102,180 beds compared to JAN's 10,422 units. In network effects, OHI leverages 94 operator relationships globally, while JAN has a highly concentrated network. For regulatory barriers, OHI is far superior, as strict State CON limits on Medicaid beds prevent new SNF construction, whereas JAN faces lower barriers in private-pay construction. For other moats, OHI's triple-net master lease structure shields it from direct expense volatility. The overall winner for Business & Moat is Omega Healthcare, as its sheer size and government-regulated barriers to entry create a highly defensive, wide-moat portfolio.

Financials show a stark contrast in profitability. On revenue growth, OHI wins with +12.0% MRQ versus JAN's +6.3% MRQ. For margins, OHI's NNN structure yields an incredible 85.0% operating margin, crushing JAN's 21.2% operating margin. On ROE/ROIC, OHI is better at 8.2% ROE compared to JAN's negative 4.9% ROE. For liquidity, JAN is better with $1.0 billion available versus OHI's $500 million available. On net debt/EBITDA, JAN's 0.0x easily beats OHI's elevated 5.0x. For interest coverage, JAN is better at infinite versus OHI's 4.2x. On FCF/AFFO, OHI is vastly better, printing $0.82 AFFO/share in Q1 2026 while JAN posted negative EPS. For payout/coverage, JAN's 0% payout provides total flexibility versus OHI's tight 86% payout. The overall Financials winner is Omega Healthcare, because despite holding higher debt, its massive margins and immediate cash flow generation make it a highly functional business today.

Past Performance favors OHI's resilience. For growth, OHI wins with +5% / +3% / +2% 1/3/5y FFO CAGR for 2021-2026 versus JAN's N/A. On margin trends, OHI expanded by +50 bps while JAN is N/A. For TSR incl. dividends, OHI wins with a +25% TSR over 5 years versus JAN's +2% TSR. On risk metrics, OHI demonstrated durability with a -30% max drawdown compared to JAN's N/A beta. The overall Past Performance winner is Omega Healthcare, which has maintained a massive dividend through severe industry turbulence, whereas JAN has no historical performance data to analyze.

Future Growth metrics expose OHI's weaknesses. TAM/demand signals are even based on the aging population. For pipeline & pre-leasing, JAN has the edge with a $1 billion unencumbered war chest versus OHI's $251 million Q1 investments. On yield on cost, OHI has the edge, securing massive 10.9% yields on recent investments versus JAN's 7.5% yields. For pricing power, JAN has the edge capturing +8.5% rent growth directly from residents, while OHI relies on fixed 2.5% escalators. On cost programs, OHI has the edge as it has zero operator cost exposure. For refinancing/maturity wall, JAN has the edge with a 0% near-term maturity wall. On ESG/regulatory tailwinds, JAN has a massive edge as its private-pay model carries zero Medicaid risk, whereas OHI constantly battles government reimbursement cuts. The overall Growth outlook winner is JAN, as its private-pay structure avoids the systemic risk of operator bankruptcies that frequently plague OHI. The risk to this view is that operating costs could spiral and compress JAN's unhedged margins.

Valuation leans heavily toward OHI for income seekers. For P/AFFO, OHI is cheaper at 14.0x compared to JAN's estimated 20.0x as of June 2026. On EV/EBITDA, OHI is cheaper at 16.5x versus JAN's 22.0x as of June 2026. For P/E, OHI is better at 20.0x while JAN is negative. On implied cap rate, OHI is better at 8.5% versus JAN's 5.5% as of June 2026. For NAV premium/discount, JAN is cheaper at a -5% discount versus OHI's +5% premium. On dividend yield, OHI is vastly superior, offering a massive 6.5% yield versus JAN's 0.0% yield. Quality vs price shows OHI offers immediate high yield at a discount multiple, while JAN is a speculative growth play. The better value today is Omega Healthcare, as it provides a fully covered, massive yield at a significantly lower cash-flow multiple.

Winner: Omega Healthcare over Janus Living. For retail investors, OHI offers a tangible, immediate 6.5% dividend yield backed by an 85% operating margin and long-term triple-net leases. Janus Living, while possessing a flawless balance sheet and avoiding government reimbursement risk, currently pays no dividend and trades at a higher multiple on future expectations. While OHI does face the constant headache of skilled nursing operator credit issues, its scale (1,124 properties) allows it to absorb and restructure these issues without breaking the dividend. JAN's 100% operational exposure to just 34 properties is simply too speculative and volatile to recommend over the established income-generating power of Omega Healthcare.

National Health Investors utilizes a hybrid approach, blending steady triple-net leased properties with a growing Senior Housing Operating Portfolio (SHOP). This makes NHI an excellent middle-ground comparison for Janus Living. While JAN is entirely committed to the volatile, high-upside RIDEA SHOP model, NHI anchors its growth with long-term fixed leases while selectively participating in operational upside. NHI offers a reliable dividend and a long history of disciplined capital allocation. JAN offers zero legacy baggage, zero debt, and a pure unadulterated bet on sunbelt senior housing.

Looking at the Business & Moat, NHI holds the advantage of diversity. For brand, NHI is larger with 200 properties compared to JAN's 34 properties. On switching costs, NHI wins with 10+ year master leases on its NNN side versus JAN's 1-2 year resident stays. For scale, NHI serves ~15,000 beds versus JAN's 10,422 units. In network effects, NHI is better, partnering with diversified national operators compared to JAN's highly concentrated legacy managers. For regulatory barriers, both are even, limited primarily by local development zoning laws. On other moats, NHI's hybrid NNN and SHOP model provides superior cash flow stability compared to JAN's pure SHOP model. The overall winner for Business & Moat is NHI, as its blended lease structure provides both upside participation and downside tenant lock-in.

Financial Statement Analysis favors NHI's operational execution. For revenue growth, NHI wins with +10.6% MRQ versus JAN's +6.3% MRQ. On margins, NHI's blended high-70s operating margin destroys JAN's 21.2% operating margin. For ROE/ROIC, NHI is better at 7.5% ROE compared to JAN's negative 4.9% ROE. On liquidity, JAN is better with $1.0 billion available versus NHI's $300 million available. For net debt/EBITDA, JAN's 0.0x beats NHI's 4.0x. On interest coverage, JAN is better at infinite versus NHI's 5.1x. For FCF/AFFO, NHI is significantly better, posting $0.82 EPS in Q1 2026 while JAN posted negative EPS. On payout/coverage, JAN's 0% payout offers total retention versus NHI's 75% payout. The overall Financials winner is NHI, because its highly functional, cash-flowing business model easily overrides JAN's mathematical lack of debt.

Past Performance is entirely one-sided. For growth, NHI wins with +8% / +4% / +3% 1/3/5y FFO CAGR for 2021-2026 versus JAN's N/A. On margin trends, NHI improved its SHOP margins by +200 bps recently, while JAN is N/A. For TSR incl. dividends, NHI wins with a +15% TSR over 5 years versus JAN's +2% TSR. On risk metrics, NHI showed stability with a -40% max drawdown during COVID, while JAN's beta is N/A. The overall Past Performance winner is NHI, which boasts a reliable history of paying dividends and navigating distressed tenants, whereas JAN has no track record.

Future Growth drivers highlight the value of JAN's cash pile. TAM/demand signals are even based on identical demographic trends. For pipeline & pre-leasing, JAN has a massive edge with its $1 billion war chest compared to NHI's $212 million YTD investments. On yield on cost, NHI has the edge, securing 8.5% yields versus JAN's 7.5% yields. For pricing power, JAN has the edge capturing +8.5% rent growth directly from wealthy seniors, while NHI's NNN side is capped at +3.0% escalators. On cost programs, NHI has the edge as its tenants bear the costs on the NNN portfolio. For refinancing/maturity wall, JAN has the edge with a 0% maturity wall. On ESG/regulatory tailwinds, both are even with their strong private-pay focus. The overall Growth outlook winner is JAN, purely because its massive relative liquidity allows it to grow its FFO at a much faster percentage rate than the mature NHI. The risk to this view is that NHI's tenant defaults could drag down its otherwise steady growth.

Valuation points to NHI as the more reasonable investment. For P/AFFO, NHI is cheaper at 17.0x versus JAN's estimated 20.0x as of June 2026. On EV/EBITDA, NHI is better at 18.0x versus JAN's 22.0x as of June 2026. For P/E, NHI is better at 22.0x while JAN is negative. On implied cap rate, NHI is better at 7.0% versus JAN's 5.5% as of June 2026. For NAV premium/discount, JAN is cheaper at a -5% discount versus NHI's +2% premium. On dividend yield, NHI is vastly superior, offering a 5.0% yield versus JAN's 0.0% yield. Quality vs price shows NHI provides a balanced, secure income stream at a fair price, while JAN requires a premium for its unproven potential. The better value today is NHI, as you are buying established cash flows at a cheaper multiple.

Winner: National Health Investors over Janus Living. NHI provides a superior, battle-tested hybrid model that gives investors the safety of long-term triple-net leases alongside the upside of a recovering Senior Housing Operating Portfolio (SHOP). NHI pays a well-covered 5.0% dividend yield and trades at a very reasonable 17.0x P/AFFO. Janus Living, while possessing a bulletproof balance sheet (0.0x debt), is entirely reliant on operational execution in just 34 properties and offers zero current yield. For a retail investor, NHI's proven management, steady FFO growth, and balanced risk profile make it a fundamentally safer and more rewarding long-term holding than the speculative JAN.

Sabra Health Care REIT is a diversified healthcare REIT with a heavy concentration in skilled nursing and behavioral health facilities, operating primarily under triple-net leases. Sabra has spent recent years restructuring troubled tenant relationships and dealing with the constraints of higher leverage. Janus Living, on the other hand, is a completely unburdened, pure-play senior housing operator focusing exclusively on high-end, private-pay residents. While Sabra offers a high dividend yield and turnaround potential, JAN offers a clean slate, zero debt, and direct exposure to the most lucrative sub-sector of healthcare real estate.

In Business & Moat, Sabra has the size but JAN has the quality. For brand, SBRA is larger with 400 properties compared to JAN's 34 properties. On switching costs, SBRA wins with multi-year NNN leases versus JAN's short-term resident agreements. For scale, SBRA serves ~40,000 beds versus JAN's 10,422 units. In network effects, SBRA leverages 70+ operators compared to JAN's narrow base. For regulatory barriers, SBRA is protected by Medicaid bed CONs whereas JAN faces lower private-pay barriers. However, for other moats, JAN wins easily; its pure private-pay model completely insulates it from the government reimbursement cuts and Medicaid insolvency risks that constantly threaten SBRA's legacy SNF operators. The overall winner for Business & Moat is Sabra on sheer size, though its moat is materially weakened by the poor credit quality of its underlying operators.

Financials show SBRA's leverage dragging down its margins. For revenue growth, SBRA wins with +12.8% MRQ versus JAN's +6.3% MRQ. On margins, SBRA is better with a ~50% operating margin compared to JAN's 21.2% operating margin. For ROE/ROIC, SBRA is better at 4.5% ROE compared to JAN's negative 4.9% ROE. On liquidity, JAN is vastly superior with $1.0 billion available versus SBRA's $500 million available. For net debt/EBITDA, JAN is perfectly positioned at 0.0x compared to SBRA's elevated 5.5x. On interest coverage, JAN is better (infinite) versus SBRA's weak 3.1x. For FCF/AFFO, SBRA generates $0.39 AFFO/share MRQ while JAN posted negative EPS. On payout/coverage, JAN's 0% payout allows for total flexibility versus SBRA's tight 80% payout. The overall Financials winner is JAN; while it lacks current earnings, its absolute lack of debt makes it fundamentally safer than SBRA's highly levered, lower-quality cash flows.

Past Performance reflects Sabra's legacy struggles. For growth, SBRA wins purely by existing, with +5% / +1% / -2% 1/3/5y FFO CAGR for 2021-2026 versus JAN's N/A. On margin trends, SBRA suffered a -100 bps margin trend while JAN is N/A. For TSR incl. dividends, SBRA barely edges out with a +10% TSR over 5 years versus JAN's +2% TSR since IPO. On risk metrics, JAN is the safer profile despite its N/A beta, as SBRA suffered a massive -50% max drawdown during recent tenant restructurings. The overall Past Performance winner is SBRA by default, but its historical performance is defined by volatility and value destruction rather than consistent growth.

Future Growth drivers heavily favor Janus Living's pure-play strategy. For TAM/demand signals, JAN has the edge as its private-pay boomer focus has far higher growth metrics than SBRA's Medicaid-reliant demographics. On pipeline & pre-leasing, JAN has a massive edge with $1 billion available while SBRA is severely constrained by its leverage profile. For yield on cost, SBRA has the edge, securing 9.0% yields on riskier SNFs versus JAN's 7.5% yields. For pricing power, JAN has the edge capturing +8.5% rent growth directly from residents versus SBRA's fixed 2.5% escalators. On cost programs, SBRA has the edge via its NNN structure. For refinancing/maturity wall, JAN has a massive edge with a 0% maturity wall versus SBRA's heavy upcoming debt maturities. On ESG/regulatory tailwinds, JAN has the edge as it holds zero Medicaid risk. The overall Growth outlook winner is JAN, as its clean balance sheet and high-quality demographic target give it an unencumbered runway. The primary risk to this view is Sabra successfully executing its turnaround and rapidly deleveraging.

Valuation shows SBRA as a deep-value play. For P/AFFO, SBRA is cheaper at 12.0x versus JAN's estimated 20.0x as of June 2026. On EV/EBITDA, SBRA is cheaper at 15.0x versus JAN's 22.0x as of June 2026. For P/E, SBRA is better at 45.0x while JAN is negative. On implied cap rate, SBRA is cheaper at 8.0% versus JAN's 5.5% as of June 2026. For NAV premium/discount, SBRA is cheaper at a -15% discount versus JAN's -5% discount as of June 2026. On dividend yield, SBRA offers a 6.0% yield versus JAN's 0.0% yield as of June 2026. Quality vs price dictates that SBRA is a distressed value trap, whereas JAN is a high-quality blank check. The better value today is SBRA strictly on mathematical multiples, but it carries immense fundamental risk.

Winner: Janus Living over Sabra Health Care REIT. While Sabra technically offers a 6.0% dividend yield and trades at a bargain 12.0x P/AFFO, it is continually bogged down by troubled skilled nursing operators, high leverage (5.5x), and heavy reliance on unpredictable government Medicare/Medicaid reimbursements. Janus Living's pristine, debt-free balance sheet (0.0x leverage) and exclusive focus on high-quality, private-pay senior housing make it a significantly safer and more attractive long-term investment. Retail investors are better off paying a slight premium for JAN's clean slate and explosive growth potential than attempting to catch the falling knife of Sabra's ongoing tenant restructurings.

Janus Living, Inc. (JAN) Competitive Analysis

Executive Summary

Comprehensive Analysis

Competitor Details

Welltower Inc.

Ventas, Inc.

CareTrust REIT, Inc.

Omega Healthcare Investors, Inc.

National Health Investors, Inc.

Sabra Health Care REIT, Inc.